[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332607-105":59,"doc-detail-332607-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nanotechnology-for-boosting-ovarian-cancer-immunotherapy","Nanotechnology for boosting ovarian cancer immunotherapy","","Ovarian cancer, often described as the “silent killer,” is difficult to detect early, leading to delayed diagnosis and poor prognosis. High mortality is driven by late detection and resistance to standard debulking surgery and platinum-based chemotherapy. Although immunotherapy and immune checkpoint inhibitors show benefits in other tumors, ovarian cancer often limits response due to an immunosuppressive tumor environment and treatment barriers. Nanotechnology-enabled delivery and advanced immunotherapy approaches may help overcome these obstacles.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nanotechnology-for-boosting-ovarian-cancer-immunotherapy/332607/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nanotechnology-for-boosting-ovarian-cancer-immunotherapy/332607.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is early detection of ovarian cancer difficult, and how does it affect outcomes?","Question",{"text":112,"@type":113},"Ovarian cancer is hard to detect in early stages, so diagnosis is often delayed until the disease is advanced. This results in poor prognosis and reduced chances of successful treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limits the effectiveness of immune checkpoint inhibitors in ovarian cancer?",{"text":117,"@type":113},"Only a few inhibitors have been effective because the tumor environment suppresses the immune system and creates barriers to treatment, which hampers existing immunotherapies.",{"name":119,"@type":110,"acceptedAnswer":120},"How does nanotechnology relate to improving ovarian cancer immunotherapy?",{"text":121,"@type":113},"Advanced nanotechnology-based delivery systems and immunotherapy approaches are proposed as promising strategies to overcome immunosuppressive conditions and improve therapeutic effectiveness.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},332607,1790107973,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Kaur et al. Journal of Ovarian Research (2024) 17:202  \n[https://doi.org/10.1186/s13048-024-01507-z](https://doi.org/10.1186/s13048-024-01507-z)  \nJournal of Ovarian Research  \nREVIEW Open Access  \nNanotechnology for boosting ovarian cancer immunotherapy  \nPrabhjot Kaur 1, Santosh Kumar Singh 1, Manoj K. Mishra2, Shailesh Singh 1,3 and Rajesh Singh 1,3*  \nAbstract  \nOvarian cancer, often referred to as the “silent killer,” is notoriously difficult to detect in its early stages, leading to a poor prognosis for many patients. Diagnosis is often delayed until the cancer has advanced, primarily due to its ambiguous and frequently occurring clinical symptoms. Ovarian cancer leads to more deaths than anyother cancer of the female reproductive system. The main reasons for the high mortality rates include delayed diagnosis and resistance to treatment. As a result, there is an urgent need for improved diagnostic and treatment options for ovarian cancer. The standard treatments typically involve debulking surgery along with platinum-based chemotherapies. Among patients with advanced-stage cancer who initially respond to current therapies, 50-75% experience a recurrence. Recently, immunotherapy-based approaches to enhance the body’s immune response to combat tumor growth have shown promise. Immune checkpoint inhibitors have shown promising results in treating other types of tumors. However, in ovarian cancer, only a few of these inhibitors have been effective because the tumor’s environment suppresses the immune system and creates barriers for treatment. This hampers the effectiveness of existing immunotherapies. Nonetheless, advanced immunotherapy techniques and delivery systems based on nanotechnology hold promise for overcoming these challenges.  \nKeywords Adoptive cell therapy, Immune checkpoint blockade, Chimeric antigen receptor T-cell therapy, Clinical trials, Ovarian cancer, Photodynamic therapy, Photothermal therapy, Myeloid-derived suppressor cells, Tumorassociated macrophages, Regulatory T cells  \nIntroduction  \nOvarian cancer (OC) is a significant health concern, particularly in developed countries, where it is the leading cause of death among gynecological malignancies. It is estimated that around 19, 710 new cases of OC were diagnosed in the United States in 2023 [1]. The primary  \n*Correspondence: Rajesh Singh [rsingh@msm.edu](rsingh@msm.edu)  \n1Department of Microbiology, Biochemistry and Immunology, Cancer Health Equity Institute, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310, USA  \n2Cancer Biology Research and Training, Department of Biological Sciences, Alabama State University, Montgomery, AL 36014, USA 3Cancer Health Equity Institute, Morehouse School of Medicine, Atlanta, GA 30310, USA  \ntreatment approaches involve surgery and chemotherapy. Unfortunately, many patients experience a recurrence of the cancer, often developing resistance to chemotherapy within a few years of their initial treatment. While there have been recent advancements in understanding the underlying biology and molecular characteristics of OC, the prognosis for women with this disease remains poor due to the high incidence of recurrence and treatment resistance. The development of chemoresistant disease leads to recurrence within 16–22 months anda low 5-year survival rate of approximately 27%. More than one-third of OC patients present with malignant ascites at diagnosis, and the development of ascites is a crucial aspect of chemoresistant and recurrent disease. The asymptomatic nature of early-stage OC often leads  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified ","cbCaigswVg2TpNpv","https://ap.wps.com/l/cbCaigswVg2TpNpv","pdf",1969270,21,"English","# Abstract\n## Background and clinical challenges\n## Standard treatments and recurrence\n## Immunotherapy and its limitations in ovarian cancer\n## Nanotechnology-based delivery and future directions","[{\"question\":\"Why is early detection of ovarian cancer difficult, and how does it affect outcomes?\",\"answer\":\"Ovarian cancer is hard to detect in early stages, so diagnosis is often delayed until the disease is advanced. This results in poor prognosis and reduced chances of successful treatment.\"},{\"question\":\"What limits the effectiveness of immune checkpoint inhibitors in ovarian cancer?\",\"answer\":\"Only a few inhibitors have been effective because the tumor environment suppresses the immune system and creates barriers to treatment, which hampers existing immunotherapies.\"},{\"question\":\"How does nanotechnology relate to improving ovarian cancer immunotherapy?\",\"answer\":\"Advanced nanotechnology-based delivery systems and immunotherapy approaches are proposed as promising strategies to overcome immunosuppressive conditions and improve therapeutic effectiveness.\"}]","Nanotechnology for boosting ovarian cancer immunotherapy | PDF",1789998895,53]